PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study.
Wu ZM, Kan J, Ye F, You W, Wu XQ, Tian NL, Lin S, Ge Z, Liu ZZ, Li XB, Gao XF, Chen J, Wang Y, Wen SY, Xie P, Cong HL, Liu LJ, Zeng HS, Zhou L, Liu F, Zheng YH, Li R, Ji HL, Zhou SH, Zhao SM, Qian XS, Luo J, Wang X, Zhang JJ, Chen SL.
Wu ZM, et al. Among authors: ye f.
Am Heart J. 2024 Nov;277:58-65. doi: 10.1016/j.ahj.2024.06.004. Epub 2024 Jun 27.
Am Heart J. 2024.
PMID: 38942221
Clinical Trial.